4.5 Article

The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population

Journal

BONE MARROW TRANSPLANTATION
Volume 35, Issue -, Pages S89-S92

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bmt.1704855

Keywords

aplastic anemia; CTLA4 polymorphisms; immunosuppressive therapy

Ask authors/readers for more resources

Aplastic anemia ( AA) is a rare disease with a major autoimmune pathogenetic component. CTLA4 is a T-lymphocyte surface molecule involved in the maintenance of immune tolerance. Some polymorphisms associated with a reduced expression of CTLA4, and thus presumably with increased tendency to autoimmunity, have been associated with various autoimmune diseases. In this study, we evaluated the distribution of the low expression polymorphisms - 318C>T and 49A>G of CTLA4 in a population of 67 patients with acquired AA and in 100 normal controls. There was no difference in the distribution of the tested polymorphism between patients and controls and, within the patient group, between those who responded to immunosuppression vs those who did not respond. This study indicates that the polymorphisms - 318C>T and 49A4G of CTLA4 do not affect the risk of developing AA and do not influence the response to immunosuppression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available